Education
About Us
Working with TipRanks
Follow Us
Austar Lifesciences Ltd. (HK:6118)
:6118
6118 Stock Chart & Stats
HK$0.89
-HK$0.02(-3.39%)
At close: 4:00 PM EST
HK$0.89
-HK$0.02(-3.39%)
Day’s Range― - ―
52-Week RangeHK$0.65 - HK$1.97
Previous CloseN/A
Volume4.00K
Average Volume (3M)695.30K
Market Cap
HK$415.19M
Enterprise ValueHK$568.54M
Total Cash (Recent Filing)HK$165.66M
Total Debt (Recent Filing)HK$357.16M
Price to Earnings (P/E)10.9
Beta0.74
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding512,582,030
10 Day Avg. Volume1,360,300
30 Day Avg. Volume695,300
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)0.35
Price to Sales (P/S)0.18
P/FCF Ratio3.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Free Cash Flow And Cash ConversionFree cash flow turned positive in 2024 and operating cash conversion is strong. Persistently positive FCF improves the company’s ability to fund R&D, support commercialization and licensing initiatives, and reduce reliance on external financing, strengthening resilience over months.
Recovery In Return On EquityROE moving from negative to positive signals improving profitability and more effective use of shareholder equity. A sustained recovery in ROE supports reinvestment capacity, helps restore investor confidence, and indicates operational fixes that can persist beyond short-term cycles.
Diversified Revenue Model (sales, Licensing, Partnerships)A multi-channel revenue model—product sales, licensing, partnerships and potential grants—reduces dependence on a single income source. Licensing and partnerships provide recurring or milestone-based cash flows and help commercialize pipeline assets, supporting steadier medium-term revenues.
Bears Say
Inconsistent Revenue GrowthNegative recent revenue growth and a choppy top-line trend undermine predictability for a development-stage biotech. Weak or inconsistent sales complicate R&D budgeting, licensing negotiations and long-term planning, making sustained margin recovery and scale harder to achieve.
Margin Pressure And Low Operating ProfitabilityRelatively low gross margin and persistently weak EBIT/EBITDA constrain free cash flow expansion and the ability to fund ongoing R&D or commercial rollouts internally. Structural margin pressure reduces buffer against cost shocks and limits long-term reinvestment capacity.
Moderate Leverage And Weakening Equity RatioModerate leverage with a declining equity ratio points to reduced financial flexibility. Continued reliance on debt or erosion of equity could increase refinancing risk and constrain strategic moves like partnerships or acquisitions, elevating balance-sheet risk over the medium term.
Austar Lifesciences Ltd. News
6118 FAQ
What was Austar Lifesciences Ltd.’s price range in the past 12 months?
Austar Lifesciences Ltd. lowest stock price was HK$0.65 and its highest was HK$1.97 in the past 12 months.
What is Austar Lifesciences Ltd.’s market cap?
Austar Lifesciences Ltd.’s market cap is HK$415.19M.
When is Austar Lifesciences Ltd.’s upcoming earnings report date?
Austar Lifesciences Ltd.’s upcoming earnings report date is Mar 31, 2026 which is in 35 days.
How were Austar Lifesciences Ltd.’s earnings last quarter?
Austar Lifesciences Ltd. released its earnings results on Aug 26, 2025. The company reported HK$0.052 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.052.
Is Austar Lifesciences Ltd. overvalued?
According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued.
Does Austar Lifesciences Ltd. pay dividends?
Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here
What is Austar Lifesciences Ltd.’s EPS estimate?
Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Austar Lifesciences Ltd. have?
Austar Lifesciences Ltd. has 512,582,030 shares outstanding.
What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?
Austar Lifesciences Ltd. reported an EPS of HK$0.052 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.758%.
Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?
Currently, no hedge funds are holding shares in HK:6118
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Austar Lifesciences Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.50%
12-Months-Change
Fundamentals
Return on Equity
4.40%
Trailing 12-Months
Asset Growth
-3.22%
Trailing 12-Months
Company Description
Austar Lifesciences Ltd.
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.
Technical Analysis
Vincent Medical Holdings Limited
―
Suzhou Basecare Medical Corp. Ltd. Class H
―
Broncus Holding Corp.
―
Yestar Healthcare Holdings Co Ltd
―
Venus Medtech (Hangzhou), Inc. Class H
―